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ABSTRACT
Immunocompromised hematopoietic stem cell transplant (HSCT) recipients frequently receive total paren-
teral nutrition (TPN), a dextrose-based solution that may exacerbate the infectious risks associated with
hyperglycemia. This study assessed the incidence of hyperglycemia (glucose level >110 mg/dL) and its effect
on clinical outcomes in TPN versus non-TPN recipients who received HSCTs. A retrospective cohort of 357
adults who were admitted for initial autologous or allogeneic transplantation at 2 university-affiliated centers
was examined. To discern the temporality of outcomes, “before” and “after” comparisons were made by using
actual infusion times for TPN patients and using timeframes based on mean hospital days before (“before”) or
during (“after”) parenteral infusion for non-TPN patients. Patients demonstrated similar demographic and
clinical characteristics when analyzed by institution, feeding, and donor-type strata, and 57% received TPN.
After attempts to equilibrate disease acuity were employed, the proportion of hyperglycemic days was
equivalent before but significantly greater after in patients exposed versus unexposed to TPN (87.5% versus
8.3%, respectively; P < .001). Using logistic regression, the likelihood of infection doubled (odds ratio [OR],
2.2; 95% confidence interval [CI], 1.4-3.5) after adjustment for donor type, diagnosis, age, gender, ethnicity,
institution, mucositis, and obesity. This association was only slightly attenuated when patients with infections
before were removed (OR, 1.9; 95%, CI, 1.1-3.3), steroid recipients were eliminated (OR, 2.1; 95% CI,
1.2-3.4), and when patients with nonablative regimens were excluded (OR, 2.1; 95% CI, 1.3-3.5), but was
considerably higher for patients who were classified as normal or underweight (body mass index <25 kg/m2;
n  118; OR, 4.3; 95% CI, 1.7-10.6). In addition, the effect of TPN became insignificant when glucose was
added as an independent variable, thus symbolizing their collinear relation. Parenteral nutrition recipients
versus nonrecipients also developed significantly greater requirements for red cell (P  .001) and platelet
transfusions (P .001) after and significant delays in granulocyte and platelet engraftment times for autologous
(P  .01) and allogeneic (P  .02) subjects. The broad use of TPN in patients undergoing initial HSCT was
associated with profound hyperglycemia, resultant greater morbidity, and questionable efficacy in this adult,
well-nourished cohort.
© 2006 American Society for Blood and Marrow Transplantation
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Impact of Hyperglycemia from Total Parenteral Nutrition on Clinical Outcomes
BNTRODUCTION
Despite signiﬁcant technologic and pharmaco-
ogic gains over the past 2 decades, infection remains
he primary cause of death among hematopoietic stem
ell transplant (HSCT) recipients [1]. Practices that
ecrease this risk are critical. Currently, there is a
rowing body of literature that demonstrates the neg-
tive relation between acute hyperglycemia and in-
reased risk of infection [2-4] and other adverse out-
omes. In the landmark trial by Van den Berghe et al
5], the dramatic decreases in morbidity, speciﬁcally a
6% decrease in bloodstream infections, and mortality
n acutely ill patients with tight blood glucose control
80-110 mg/dL) versus conventional blood glucose
evels (180-200 mg/dL) not only necessitated early
ermination of the study but also highlighted a poten-
ial target to improve health outcomes in hospitalized
atients.
Total parenteral nutrition (TPN) has commonly
een administered to HSCT patients since the early
980s [6,7]. It is classically initiated to assist in the
anagement of the diarrhea, nausea, vomiting, an-
rexia, and ﬂuid and electrolyte disorders that accom-
any the transplantation process and to prevent or
reat malnutrition. However, the advent of growth
actors and the use of peripheral blood have signiﬁ-
antly decreased the number of days to engraftment
8] and the consequent time of inadequate oral intake.
espite expense, its inherent risks, and lack of trials
emonstrating the efﬁcacy of TPN in this patient
opulation, it continues to be a recommended com-
onent of transplant care [9]. As a consequence, ad-
inistration of this dextrose-based solution in a pop-
lation prone to infection may unknowingly
ompound the blood glucose aberrations associated
ith transplantation [10] and result in untoward
ather than beneﬁcial effects. This study assessed the
ncidence of hyperglycemia and its association with
arious clinical outcomes known to be exacerbated by
cute blood glucose increases in comparable TPN
ersus non-TPN transplant recipients.
ATERIALS AND METHODS
tudy Design
A retrospective cohort investigation was con-
ucted by using the medical records of patients who
ad an initial HSCT between September 1999 and
ecember 2003 at 2 urban university hospitals. This
esign was selected because it provided an efﬁcient,
nexpensive means of examining our hypotheses with
inimal risks to patients; allowed for precise docu-
entation of exposure (initiation and termination of
PN), major outcomes (hyperglycemia, infection),
nd vital confounding factors (e.g., conditioning che-
otherapy, quantity of CD34 cells transplanted, etc) m
B&MTqually for all patients; and allowed for accurate as-
ertainment of incidence rates, temporality of out-
omes, and dose-response measurements for expo-
ures between groups.
tudy Population
All patients who were 18 years of age and ad-
itted to 2 university-afﬁliated transplantation cen-
ers for an initial autologous or allogeneic HSCT were
ligible for inclusion. This patient population was
elected because it manifested several optimal charac-
eristics: (1) a 50-60% TPN exposure rate uniformly
elivered through a central line; (2) comparable base-
ine cardiac, pulmonary, renal, and hepatic functions;
nd (3) increased susceptibility to infections due to
mmunosuppression, thus increasing the number of
bservable outcomes. Individuals who had a history of
ome TPN administration, were admitted with a doc-
mented infection, or were 18 years old were ex-
luded.
ata Collection
Institution-speciﬁc transplantation databases were
btained and screened for initial eligibility while
orking retrospectively. Computerized and hardcopy
edical records were used. Baseline data were ex-
racted from physicians’ history and physical exami-
ations. Preparative chemotherapeutic regimens were
eriﬁed from the pharmacy chemotherapy dosing
ecords. Culture results and daily blood draws were
btained from the laboratory reports. Admission
eight and weight and TPN dose, volume, and dura-
ion were collected from the initial nutritional evalu-
tion and from pharmacy records. Nursing progress
otes were used for daily weights, maximum temper-
tures, and 24-hour intake and output volumes. Doc-
mentation of mucositis was gathered from physician
nd/or nursing daily progress notes. Blood bank sum-
aries were used to conﬁrm red cell and/or platelet
ransfusions. Transplant records were used to verify
he number of CD34 cells transplanted. Granulocyte
nd platelet engraftments were deﬁned as the number
f days between transplant day 0 and the ﬁrst day of 3
onsecutive days that the absolute neutrophil count
as .5  109/L or when platelets were 50 
09/L, respectively. Nutritional status was assessed by
sing admission serum albumin level, admission body
ass index (BMI), and percentage of ideal body [11].
utcome Measurements
The primary outcome measurement was hyper-
lycemia, which was also analyzed as an independent
ariable. Glucose was recorded once per day from the
rst morning venous blood draw to achieve unifor-
ity among patients, avoid measurements that occur
ore frequently among hyperglycemic patients, and
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6inimize the inﬂuence of oral intake. Total number
f days and percentage of hospital days with blood
lucose levels110 [4] and200 mg/dL were used to
valuate 2 levels of hyperglycemic events. Information
n exogenous insulin administration was not col-
ected. Secondary outcome measurements were num-
er of infections, red cell and platelet transfusions, white
lood cell (WBC) count and platelet engraftment, and
yperlipidemia. At both institutions, blood cultures were
outinely procured for temperatures 38°C (100.5°F),
tool cultures were sent for Clostridium difﬁcile with com-
laints of or documentation of diarrhea, and red cells and
latelets were typically transfused to maintain a hemo-
lobin level 8 g/dL and platelet count 10-20 
03/L. To determine platelet engraftment, it was
equired that patients demonstrate platelet transfu-
ion independence (ie, levels assessed 7 days after
latelet transfusion) and that platelet levels decrease
o 50  109/L to signify a platelet nadir. Routine
urveillance cultures were not included, and cul-
ure-positive and culture-negative infections were
ounted only if documented and treated by the
ttending physician. Although triglyceride monitor-
ng is not routine in this patient population, in an
ttempt to discern whether differences in hyperlip-
demia occurred between TPN and non-TPN pa-
ients, a sample of 20 patients in each group who had
riglyceride levels measured were examined for mean
riglyceride values.
omparability of TPN and Non-TPN Participants
Several steps were taken to demonstrate compara-
le disease acuity between the TPN and non-TPN
roups before TPN exposure. First, patients who typ-
cally develop higher rates of transplant-related com-
lications and mortality were not eligible for inclusion
eg, matched unrelated donor, tandem, or subsequent
ransplants), thereby eliminating potentially sicker or
typical transplant candidates. Second, vital clinical
haracteristics were compared between groups and
atients who seemed principally different were re-
oved. Speciﬁcally, to minimize the risk of undiag-
osed diabetes mellitus or underlying acute illness,
atients with consistently elevated blood glucose val-
es, temperatures, or WBC counts on admission were
liminated. Third, nutritional status at admission was
ompared across groups because depleted serum albu-
in and BMI have been shown to be valid indicators of
nfavorable hospital outcomes [12]. Fourth, to deter-
ine temporal changes in hyperglycemia, infections,
nd blood product support, standardized timeframes,
eferred to as “before” and “after” TPN exposure,
ere created. In patients who received TPN, actual
ays before TPN and during TPN infusion were used
nd categorized as “before” and “after.” Because the
on-TPN group did not actually receive TPN, the s
58efore and after intervals were created for these pa-
ients as follows: “before” (pre-TPN time) indicated
he transplant-speciﬁc mean number of days before
PN initiation as assessed for TPN patients (10 days
or autologous, 13 days for allogeneic) and “after”
post-TPN time) indicated the transplant-speciﬁc
ean number of TPN infusions days as assessed in
atients who received TPN (11 days for autologous,
6 days for allogeneic).
ata Quality
To assure reproducible and accurate data points, a
outine data collection procedure was used to identify,
ocate, and verify data within the medical record (eg,
hysician documentation of infection conﬁrmed by
aboratory reports). Quality assurance was performed
y having an individual who was not involved in the
tudy examine 2-4 records per month, and discrepan-
ies were resolved by consensus and developing meth-
ds to prevent future errors. All data were double-
ntered and cleaned in Epi Info 6 [13]. This study was
pproved by the institutional review boards at both
enters.
tatistical Analyses
Means, medians, SDs, and ranges were used to
xamine and describe the distribution of data and
tudent t, chi-square, and Wilcoxon rank-sum tests
ere used to compare clinical and demographic char-
cteristics between institutions, feeding strata, and do-
or types. Subsequent analyses concentrated on the
ain effects of TPN exposure on outcomes, with
tratiﬁcation by donor type when applicable. Multiple
ogistic regression analysis was conducted to ascertain
dds ratios (ORs) and 95% conﬁdence intervals (CIs) for
he association between TPN exposure and infection.
tatistical analysis was conducted with SAS 9.1 [14].
ESULTS
tudy Population
A total of 380 patients qualiﬁed based on donor
ype and initial transplant. Of these, 23 patients were
xcluded (15 were admitted with an active infection
hat required treatment, 7 had insufﬁcient medical
ecord documentation or atypical admissions, and 1
as on home TPN), leaving 357 for analyses. Overall,
PN exposure occurred in 57% of the cohort, with
nly minimal variations in exposure rates by study
ear. When TPN was analyzed according to attending
hysician use, exposure patterns ranged from 20% to
7%, symbolizing within-physician practice varia-
ions. Institutional differences were reﬂected in pa-
ient demographics, admission albumin level, length
f stay, and preparative chemotherapeutic regimens,
peciﬁcally with regard to the use of rituximab, total
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Body irradiation, and/or cyclophosphamide (Table 1).
isparities between TPN strata were detected for
rimary disease (signiﬁcantly more patients with non-
odgkin lymphoma and fewer with multiple myeloma
eceived TPN), which reﬂected preparative chemo-
herapeutic differences.
Most patients were well nourished at admission,
ith a clinically insigniﬁcant trend toward higher lev-
ls of albumin in the non-TPN than in the TPN
roup. Using BMI classiﬁcations from the Centers for
isease Control and Prevention [15], the average trans-
lant recipient was overweight (BMI 25 kg/m2), with
able 1. Baseline Patient Characteristics by Institution and by TPN St
Hospital A
atients 250
Male 152 (61)
Female 98 (39)
ge, y 48.4  13.1
ace
White 152 (61)
AA 52 (21)
Hispanic 35 (14)
Other 11 (4)
rimary disease
Multiple myeloma 85
Non-Hodgkin lymphoma 69
Acute myeloid leukemia 18
Hodgkin lymphoma 21
Other diagnosis‡ 57
ype of transplant
Autologous 171 (68)
Allogeneic 79 (32)
arnofsky score 92  5
reparative chemotherapy - n
Carmustine, etopside, cytarabine,
melphalan  rituximab 35/31
Melphalan  fludarabine 75/26
Total body irradiation  cyclophosphamide§ 75
Other chemotherapy 8
istory of DM 29 (12)
Insulin requirement 13
Oral agents 13
Diet controlled 3
dmission glucose, mg/dL 116  53
teroid use, % 12
utritional status
Body mass index, kg/m2 28.0  6.2
Albumin, g/dL 3.3
Ideal body weight, % 126
dmission temperature, °F 98.7  0.8
dmission WBC, 103/L 7.3  8.1
ength of stay, d 24  8
live at discharge 244 (98)
A indicates African American; DM, diabetes mellitus.
Values are numbers (%) of patients or mean  SD.
P values were determined with the use of Student t test, Wilcoxo
Other diagnoses included smaller clusters of chronic myelogen
lymphocytic leukemia (n  13), renal cancer (n  8), breast can
testicular cancer (n  2), myeloﬁbrosis (n  5), and other diag
Chemotherapy included a combination of 1 or both of these agen
Various combinations of busulphan, carmustine, etoposide, ﬂudara5% meeting obesity qualiﬁcations (BMI 30 kg/m2), p
B&MTegardless of institution, TPN grouping, or diagnosis,
nd only 7 patients were classiﬁed as underweight
BMI18.5 kg/m2). Signiﬁcantly more non-TPN pa-
ients had diabetes mellitus (Table 1). In addition,
igniﬁcantly more TPN patients received steroids
uring hospitalization compared with non-TPN pa-
ients (P  .001), beginning typically on hospital day
4 and ending on hospital day 33. Although all allo-
eneic patients received graft-versus-host disease
GVHD) prophylaxis using methotrexate, acute
VHD was documented in 22 patients (19 received
PN and 21 received steroids) and signiﬁcantly larger
 357)*
ital B P† TPN No TPN P
7 202 155
(52) .14 115 (57) 93 (60) .56
(48) 87 (43) 62 (40)
12.7 .67 47.6  13.2 50.3  12.6 .06
(37) <.001 115 (57) 77 (49) .17
(37) .001 46 (23) 46 (30) .14
(21) .12 29 (14) 28 (18) .34
(5) .91 12 (6) 4 (3) .20
3 .26 60 68 .006
2 .16 61 30 .02
2 .21 18 12 .69
6 .36 16 11 .77
4 .94 47 34 .77
(69) .89 129 (64) 116 (75) .03
(31) 73 (36) 39 (25)
5 .57 92  5 92  5 .84
/0 .08/<.001 36/23 22/8 .36/.04
/18 .09/.09 52/29 65/15 <.001/.18
7 .005 51 41 .80
7 .15 11 4 .29
(16) .27 19 (9) 27 (17) .03
4 .21 8 9 .54
0 .36 9 14 .76
3 .66 2 4 .99
37 .82 116  57 115  36 .80
5 .38 19 4 <.001
7.1 .15 27.6  6.2 29.3  6.6 .02
3.5 <.001 3.3 3.4 .06
3 .06 125 132 .04
0.9 <.001 98.6  0.9 98.5  0.8 .29
7.1 .59 8.3  11.9 6.5  5.1 .05
7 .02 27  9 20  4 <.001
(91) .004 187 (93) 154 (99) .001
sum test, chi-square test, or Fisher exact test, as appropriate.
kemia (n  20), acute lymphocytic leukemia (n  9), chronic
 6), myelodysplastic syndrome (n  6), aplastic anemia (n  2),
n  10).
or without others.
elphalan, and/or rituximab.atus (n
Hosp
10
56
51
49.6 
40
40
22
5
4
2
1
2
74
33
92 
23
42
1
17
1
115 
1
29.1 
13
98.1 
7.1 
22 
97
n rank-
ous leu
cer (n
noses (
ts withroportions of hospital days with mucositis were ex-
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6erienced by TPN patients compared with non-TPN
atients (25.8  22.8% versus 14.4  19.7%, respec-
ively; P  .001). When triglyceride levels were ana-
yzed in a subset of TPN (n 20) and non-TPN (n
0) subjects, similar values were found (156 versus 154
g/dL, respectively). Number of hospital days until
PN initiation, TPN duration, total kilocalories, and
rams of protein were not signiﬁcantly different by
nstitution but were markedly different by donor type
Table 2).
lood Glucose Control
Blood glucose values were plotted longitudinally
or all patients throughout hospitalization (ie., average
lood glucose for all participants each hospital day
hen n  50). Figure 1 shows that all patients devel-
ped increases in blood glucose during the ﬁrst few
ays of hospitalization due to the catabolic nature of
onditioning chemotherapy, with a return to lower
evels in subsequent days. A clear divergence between
urves is noted by hospital day 10 as a reﬂection of
able 2. Total Parenteral Nutrition Practices by Institution and Donor
Hospital A Hospital B
o. patients 149/250 39/107
PN initiation day 12  4 13  3
PN duration, d 13  7 12  7
otal kilocalories 1813  306 1727  350
ilocalories† 26  3 26  5
rotein‡ 1.2  0.2 1.2  0.3
ipid emulsion§ 98% 97%
Values are means  SD. These totals exclude patients with 4 da
Number of kilocalories per kilogram of body weight adjusted for
Number of grams of protein per kilogram of body weight adjuste
Percentage of patients who received lipid emulsion as a componeFigure 1. Glucose across time as stratiﬁed by TPN for all pa
60PN initiation; however, this did not change when
teroid recipients, patients with diabetes mellitus, or
hose who died at discharge were removed (Figure 2)
r when plotted by donor type. When dichotomized,
he median proportion of hyperglycemic days for all
atients was not statistically different before (40.0% of
PN subjects versus 38.4% of non-TPN subjects; P
.77) but was markedly different after (87.5% of
PN subjects versus 12.5% of non-TPN subjects; P
.001); this difference remained when stratiﬁed by
onor type and after patients who received steroids
ere removed. In addition, when conventional hyper-
lycemia deﬁnitions were used (200 mg/dL, or 11.1
mol/L), only 11% of TPN patients (n 22) and 1%
f non-TPN patients (n  1) were classiﬁed as hyper-
lycemic (mean blood glucose level, 237 mg/dL, or
3.2 mmol/L).
orbidity
Total infections and blood product support were
nalyzed according to the before and after periods as
P Autologous Allogeneic P
118/245 70/112
.08 11  3 14  5 <.001
.74 11  5 16  9 <.001
.13 1796  306 1794  336 .97
.82 26  4 26  4 .33
.48 1.3  0.2 1.2  0.2 .29
.99 98% 97% .99
PN exposure.
, when applicable.
besity, when applicable.
PN.Type*
ys of T
obesity
d for otients (n  50). TPN  line 1, Non-TPN  line 2.
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Btratiﬁed by TPN exposure. To control further for
everity of illness, patients were eliminated if they
ere infected before. Regardless, total infections after
ere .8  1.0 versus .4  .6 in TPN versus non-TPN
ubjects, respectively. Red cell and platelet supports
id not differ in the TPN groups before, but consid-
rable differences were detected after when compar-
ng TPN with non-TPN subjects (Table 3). When
urther stratiﬁed by donor type, no signiﬁcant varia-
ions occurred before, but signiﬁcant differences
cross TPN strata were detected after in allogeneic
atients with regard to total infection (P  .001) and
ed cell (P .001) and platelet (P .001) transfusions
nd in autologous patients with regard to red cell and
latelet transfusions. In a multiple logistic regression
odel, TPN recipients were 2 times more likely to
ecome infected than were non-TPN recipients (OR,
.2; 95% CI, 1.4-3.5) for the entire cohort, after
ontrolling for donor type, diagnosis, age, gender,
thnicity, institution, mucositis, and obesity. This as-
ociation decreased only slightly when patients with
nfections before were removed (OR, 1.9; 95% CI,
.1-3.3), steroid recipients were eliminated (OR, 2.1;
5% CI, 1.2-3.4), and when patients with nonablative
egimens were excluded (OR, 2.1; 95% CI, 1.3-3.5).
Figure 2. Glucose across time as stratiﬁed by TPN w
able 3. Incidence and Temporality of Infection and Blood Product Sup
TPN
Before After
otal infection 0 0.8  1.0
ed cell support 1.2  1.4 3.3  3.2
latelet support 0.7  1.9 5.7  6.6
Values are means  SD; n  258 after elimination of infected pa
TPN after versus. non-TPN after.
B&MTowever, when the analysis was restricted to patients
ho had normal weight or were underweight (BMI
25 kg/m2; n  118), the odds of infection increased
onsiderably (OR, 4.3; 95% CI, 1.7-10.6).
Next, TPN subjects were categorized according to
ean glucose values during TPN infusion (Table 4).
he incidence of infection increased as mean glucose
alues increased, which was more pronounced in sub-
ects without an infection before. To examine the odds
f infection by length of time exposed to TPN, a
ertile-split TPN variable was created (0  no TPN,
 1-7 days, 2  8-12 days, 3  12 days). Using a
imple logistic regression model, crude ORs (95%
Is) for the association between infection and length
f time exposed to TPN were 1.0 (referent), 1.5 (1.2-
.8) for 1-7 days, 2.2 (1.5-3.1) for 8-12 days, and 3.2
1.8-5.5) for 12 days; these values were only slightly
ttenuated after controlling for glucose.
ngraftment
Within this cohort, 99% (n  352) of patients had
eripheral blood as the sole source of stem cells, all
ere treated with colony-stimulating factors accord-
ng to predetermined institution protocols, and the
usions (n  50). TPN  line 1; Non-TPN  line 2.
atiﬁed by TPN* (n  258)
Non-TPN
Before After P†
0 0.4  0.6 .03
1.2  1.5 1.5  1.8 <.001
0.4  1.0 2.3  2.7 <.001
efore.port Str
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6umber of infused CD34 cells for TPN and non-
PN patients were not signiﬁcantly different, regard-
ess of donor type. Despite these similarities that di-
ectly inﬂuence engraftment time, signiﬁcant differences
ere detected in posttransplant days untilWBC engraft-
ent for autologous (11.9  2.4 versus 11.2  1.9 days;
 .01) and allogeneic (14.8  4.8 versus 12.3  2.5
ays; P  .001) patients who received TPN compared
ith those who did not.
According to criteria similar to those of Cetin et
l. [16], platelet levels decreased to 50  109/L in
46 subjects, with most patients exhibiting levels 20
109/L (n  304). Because 237 patients were not
ndependent of transfusions and an additional 17 sub-
ects did not achieve levels 50  109/L, 92 subjects
emained for analyses. Of these, signiﬁcantly longer
eriods until platelet engraftment were found for au-
ologous (16.6  4.9 versus 12.9  2.6 days; P  .004;
 51) and allogeneic (19.8  5.1 versus 15.3  4.8
ays; P  .02; n  41) patients who received TPN
ersus those who did not.
ISCUSSION
We determined that there were profound differ-
nces in the incidence of hyperglycemia in TPN ver-
us non-TPN recipients, and that hyperglycemia as a
onsequence of TPN exposure was associated with
ore infections, blood product support, and delayed
ranulocyte engraftment and platelet engraftments in
cohort of HSCT recipients. Several previous inves-
igators have demonstrated the importance of short-
erm glycemic control on clinically important out-
omes in hospitalized patients [2-5,17-22]; however,
o our knowledge, no one has directly assessed the
nﬂuence of hyperglycemia and its resultant morbidi-
ies a priori in TPN versus non-TPN patients.
The early studies by Weisdorf et al. [6,7] associ-
ted prophylactic versus ad libitum TPN with earlier
ngraftment and prolonged survival. Although these
nvestigations are widely cited as the rationale behind
PN use during transplantation, changes in patient
opulation and clinical management methods since
he 1980s have made them increasingly difﬁcult to
pply to modern practice. In addition, considering
able 4. Dose-Response Relation between Blood Glucose and Infections f
<109 mg/dL 110-135 m
o. patients 28 69
Total infections 0.6  1.0 0.6  0
o. patients 23 46
Total infections‡ 0.4  0.7 0.7  0
Values are means  SD.
P for trend.
TPN subjects without infection before (n  138).hat 73% [6] and 60% [7] of control patients in the
62tudies by Weisdorf et al. actually received TPN, the
roups’ treatments were homogeneous, making deter-
ination of TPN exposure on outcomes difﬁcult to
valuate and diminished the rationale for its routine
se unsubstantiated. To date, TPN administration has
een shown to be beneﬁcial for patients who are
everely malnourished [23]. By using comparable BMI
utpoints as a crude measurement of nutritional status
underweight, BMI 18.5 kg/m2), we found that only
% (n  7/357) of our cohort was classiﬁed as mal-
ourished, although 44% of all TPN recipients were
verweight or obese (n  89/202). Although this
eneralization is limited by the lack of information on
eight history or oral intake, it does support the obser-
ations of Muscarotoli et al. [24] that TPN is often
rovided during transplantation irrespective of nutri-
ional status. Considering the paucity of studies that
upport the efﬁcacy of TPN during transplantation
nd the fact that infection remains their leading cause
f death [1], the concept of permissive underfeeding
nd its effect of transplantation outcomes warrants
urther investigation.
Parenteral nutrition has proved to be life-saving in
umans with permanent gastrointestinal failure, but it
as inherent risks, most appreciably, a greater risk of
nfection when compared with enteral tube feeding
25-31] or standard oral diets [32]. Some have specu-
ated that this increased risk is due to bacterial trans-
ocation after atrophy of the gut mucosa and gut-
ssociated lymphoid tissue [33,34]. We hypothesized
hat the higher incidence of infection among those
nitially free of infection was a result of TPN-induced
yperglycemia, which impaired granulocyte adher-
nce [35], chemotaxis [36], phagocytosis [37], and mi-
robicidal cell functions [38]. In our simple logistic
egression model, TPN exposure and hyperglycemia
emained signiﬁcant predictors for infection, suggest-
ng that other attributes of TPN administration may
ontribute to the observed increased risks. Further,
ecause pancytopenia occurred around the average
ime of TPN initiation, it is biologically plausible that
he hyperglycemic environment may have delayed
eutrophil recovery, impeded nascent neutrophil
unction, and ultimately promoted greater infections
nd prolonged engraftment times.
Subjects* (n  200)
136-160 mg/dL >160 mg/dL P†
47 56 .08
0.7  0.8 1.0  1.3
33 86
0.8  0.9 1.2  1.5 .04or TPN
g/dL
.8
.8We speciﬁcally selected a retrospective study de-
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Impact of Hyperglycemia from Total Parenteral Nutrition on Clinical Outcomes
Bign due to its strengths of efﬁciency and speed. How-
ver, because of its retrospective nature, it was imper-
tive for us to demonstrate comparability in those
xposed versus unexposed to TPN for valid outcome
omparison. To this end, less common donor types
nd patients with differences in baseline admission
haracteristics known to predict adverse outcomes
ere eliminated, thus collectively minimizing patients
ho are predisposed to increased morbidity. Next,
ntensive efforts to discover differences between feed-
ng strata were employed. Nominal variations at base-
ine for demographic and transplant characteristics
ere revealed, and crude measurements of nutritional
tatus and the incidence of hyperglycemia before ap-
eared equivalent for TPN versus non-TPN subjects,
hus reﬂecting an overall comparability between
roups. Traditionally, prospective trials are cited as
he gold standard for the determination of causality;
owever, they have to be adequately powered for
qual randomization of known and unknown con-
ounders. Because an illness acuity scoring system is
acking for this patient population, there is no cur-
ently available method to evaluate the effectiveness of
andomization. Thus a large sample would be re-
uired to decrease the risks of unbalanced distribution
f unknown confounders, thus necessitating a multi-
enter trial or a long investigation period. Therefore,
espite the expanded understanding of the role of
PN on hyperglycemia and hyperglycemia-related
orbidities that a prospective clinical trial could offer,
he negative outcomes that were found from its expo-
ure and the continued inability to assess severity of
isease between TPN and non-TPN patients has lim-
ted our enthusiasm for this type of investigation in
his population.
The limitations of this study should be noted.
irst, although we believe our efforts were successful
n equilibrating disease acuity between TPN and non-
PN patients, the potential for these groups to be
undamentally different remains. Consistent clinical
riggers of TPN initiation were not apparent. When
e analyzed within-physician patterns of TPN expo-
ure, these ranged from 20% to 77%. Therefore, we
oncluded that TPN administration was largely dic-
ated by physician clinical judgment, which served as a
orm of randomization. Further, to eliminate con-
ounding effects the sickest patients may have had on
he outcomes and strengthen our ﬁndings, during data
nalysis patients with infections in the time preceding
PN (n  94) or those with a history of diabetes
ellitus, intensive care unit admission, or death at
ischarge (n  57) were eliminated. Despite these
xclusions, disparities in blood glucose control with
egard to incidence, temporality, and dose-response
nd disparities in blood product support remained
igniﬁcant between TPN and non-TPN patients,
ven after stratiﬁcation by donor type. Differences in
B&MTnfection after were not signiﬁcant in the autologous
atients due to inadequate statistical power, but sig-
iﬁcant differences in infection after remained for
llogeneic patients (P .02). Second, because mucosi-
is is associated with conditioning chemotherapy and
ften methotrexate use, it can be a major predictor of
PN initiation and predispose individuals to infec-
ion, making it difﬁcult to discern its direct inﬂuence
n the outcomes of interest. However, despite con-
rolling for conditioning chemotherapy and the uni-
orm use of methotrexate in those who required
VHD prophylaxis, mucositis was not a signiﬁcant
redictor of infection and it did not attenuate the
ssociations observed when added to the regression
odels. Third, although we found equivalent triglyc-
ride levels between TPN and non-TPN recipients,
e were unable to determine the true effect of
ypertriglyceridemia on infectious risk because
hese values are not routinely and uniformly col-
ected for all transplant recipients. Fourth, although
e cannot account for the potential effect of insulin
dministration on outcomes, we believe this was
inimal because most of the blood glucose values
ere 200 mg/dL, which do not typically prompt
xogenous insulin support.
Globally, the use of TPN was signiﬁcantly asso-
iated with hyperglycemia and untoward events in a
eterogeneous group of patients who received initial
SCTs and when examined by donor type. Further
tudies are needed to address the overall efﬁcacy of
PN use in well-nourished, adult transplant popula-
ions; and until experimental evidence is available,
lood glucose levels should be frequently monitored
uring TPN administration and should not exceed
50 mg/dL.
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